alexa Development Of Etanercept Biosimilar ErelziTM
ISSN: 1948-593X

Journal of Bioanalysis & Biomedicine
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading
Loading Please wait..
 

7th European Biosimilars Congress
May 15-16, 2017 Munich, Germany

Tim Demuth, Antonio Da Silva, Martin Schiestl and Cornelius Fritsch
Sandoz Pharmaceuticals GmbH, Germany
ScientificTracks Abstracts: J Bioanal Biomed
DOI: 10.4172/1948-593X-C1-026
Abstract
GP2015 has been developed as a biosimilar to Enbrel® (etanercept) and was approved as Erelzi by US FDA in August 2016. Assessment of biosimilarity follows the totality-of-the-evidence concept taking into consideration physicochemical, biological, nonclinical and clinical data. Biosimilarity to the approved originator product is confirmed in a step-wise approach. Characterization of multiple originator batches was conducted over time followed by an iterative, target-directed development process to yield a product falling into the variability range of the originator. Biosimilarity between GP2015 and the originator was confirmed at analytical, functional, nonclinical, pharmacokinetic (PK) and clinical levels. Bioequivalence between GP2015 and the originator was assessed in PK studies in animals and healthy volunteers. To detect clinically meaningful differences between GP2015 and originator, efficacy, safety and immunogenicity was studied in patients with moderate to severe chronic plaque type psoriasis. This phase III confirmatory study assessed the Psoriasis Area and Severity Index response rate at weeks 12, 30 and 52. ErelziTM was developed at the same dosage and strength as the originator. Multiple analytical methods showed high similarity between GP2015 and the originator. The amino acid sequence was confirmed to be identical and protein folding was indistinguishable. In-vitro assays showed GP2015 and the originator had similar bioactivity. PK bioequivalence between GP2015 and the originator was established in nonclinical and human studies. The study in patients with psoriasis confirmed similar efficacy and safety and comparable immunogenicity in a highly sensitive indication. In all studies, no clinically meaningful differences between GP2015 and the originator were observed. Analytical, functional, nonclinical and clinical data provide comprehensive understanding of GP2015 and the originator and demonstrate a high level of similarity between the two substances in accordance with regulatory requirements. The totality of evidence of biosimilarity justifies the use of the biosimilar in the same indications as Enbrel® and was confirmed by FDA.
Biography

Tim Demuth, MD is a Clinical Development Unit Head at Sandoz Biopharma responsible for clinical strategy, and execution of biosimilar development programs. He has extensive experience in early and late stage drug development across multiple therapeutic areas including immunology, hematology and oncology. He has great passion for innovative approaches to drug development with the aim to improve patient access to medicines.

Email: [email protected]

image PDF   |   image HTML
 
Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

 
© 2008- 2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords